The mission of the Curative Therapies for HIV Scientific Working Group (SWG) is to encourage the development of a cure for HIV, by fostering new ideas and promoting new technology. During the previous funding cycle this continuing SWG was highly successful in its efforts to bring together local researchers and community members with the aim of advancing cure research. As the HIV pandemic continues to affect many millions of lives globally, there is still an urgent need for an HIV cure, so we will continue to support research into curative therapies through our SWG. The long-term objective of our SWG is to stimulate novel research, which can progress into a cure for HIV that can ultimately be transitioned into the clinic, and reduce the global burden of HIV that remains. To achieve our mission the SWG will continue to bring together UW/Fred Hutch CFAR affiliated researchers, unaffiliated external HIV researchers, and community members, through a series of scientific networking events, forums and an annual conference, each with a defined purpose. The goals of this SWG will be attained through two specific aims that are intended to: 1) Provide infrastructure that fosters the exchange of new actionable ideas, engages the community, and promotes the development of novel curative treatments for HIV, and 2) Develop new intra-/inter-CFAR projects and funding applications on curative therapies for HIV. Cooperation between researchers and community members from local, national and international settings who are invested in the common goal of HIV cure will be key to the success of our mission. We plan to leverage recent NIH investment in the Seattle-led consortium defeatHIV, one of six Martin Delaney Collaboratories focused on the cure of HIV. We will work with UW/Fred Hutch CFAR cores and external researchers to exploit expertise across many areas, in order to develop novel research questions and subsequent grant applications for the study of curative therapies for HIV. We will also work closely with local, national, and international community members to learn what an HIV cure would mean to them, and to gain new perspectives into how an HIV cure can be realized. Collaboration is essential to our mission, and by working with people of broad experience and from diverse backgrounds we hope to serve as an internationally-recognized center for the study of curative therapies for HIV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI027757-31
Application #
9534845
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
31
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Fredericksen, Rob J; Mayer, Kenneth H; Gibbons, Laura E et al. (2018) Development and Content Validation of a Patient-Reported Sexual Risk Measure for Use in Primary Care. J Gen Intern Med 33:1661-1668
Wilson, Kate S; Wanje, George; Masese, Linnet et al. (2018) A Prospective Cohort Study of Fertility Desire, Unprotected Sex, and Detectable Viral Load in HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 78:276-282
Ikoma, Minako; Gantt, Soren; Casper, Corey et al. (2018) KSHV oral shedding and plasma viremia result in significant changes in the extracellular tumorigenic miRNA expression profile in individuals infected with the malaria parasite. PLoS One 13:e0192659
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Gómez, Laurén A; Crowell, Claudia S; Njuguna, Irene et al. (2018) Improved Neurodevelopment After Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus-infected Children. Pediatr Infect Dis J 37:916-922
Thomson, Kerry A; Dhanireddy, Shireesha; Andrasik, Michele et al. (2018) Fertility desires and preferences for safer conception strategies among people receiving care for HIV at a publicly-funded clinic in Seattle, WA. AIDS Care 30:121-129
Lohman-Payne, Barbara; Gabriel, Benjamin; Park, Sangshin et al. (2018) HIV-exposed uninfected infants: elevated cord blood Interleukin 8 (IL-8) is significantly associated with maternal HIV infection and systemic IL-8 in a Kenyan cohort. Clin Transl Med 7:26
McGrath, Christine J; Singa, Benson; Langat, Agnes et al. (2018) Non-disclosure to male partners and incomplete PMTCT regimens associated with higher risk of mother-to-child HIV transmission: a national survey in Kenya. AIDS Care 30:765-773
Njuguna, Irene N; Wagner, Anjuli D; Omondi, Vincent O et al. (2018) Financial Incentives for Pediatric HIV Testing in Kenya. Pediatr Infect Dis J 37:1142-1144

Showing the most recent 10 out of 1275 publications